Search

Your search keyword '"Rousselot, Philippe"' showing total 76 results

Search Constraints

Start Over You searched for: Author "Rousselot, Philippe" Remove constraint Author: "Rousselot, Philippe" Database Complementary Index Remove constraint Database: Complementary Index
76 results on '"Rousselot, Philippe"'

Search Results

1. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

2. Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients.

4. Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.

5. Novel precision medicine approaches and treatment strategies in hematological malignancies.

6. Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM study.

7. UV exploration of the solar system.

8. AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome.

9. Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak.

10. Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia.

11. KMT2A-ARHGEF12, a therapy related fusion with poor prognosis.

12. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.

13. Rapid screening of COVID‐19 patients using white blood cell scattergrams, a study on 381 patients.

14. PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE‐BASED THERAPY.

15. P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3‐YEAR UPDATE OF THE OPTIC TRIAL: A DOSE‐OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB.

16. EWALL-TARGET for Precision Therapy in Relapsed/Refractory T-ALL.

17. Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.

18. OSSOS: XI. No active centaurs in the Outer Solar System Origins Survey.

19. The story of tyrosine kinase inhibitors discontinuation in clinical practice.

21. Common clonal origin of an EBV-positive diffuse large B cell lymphoma and a chronic myelomonocytic leukemia.

22. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

23. Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.

24. DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+CD15− cells in early chronic‐phase chronic myeloid leukemia.

25. Dasatinib dose management for the treatment of chronic myeloid leukemia.

26. Diagnostic et gestion des effets secondaires pleuropulmonaires des inhibiteurs de tyrosine kinase Recommandations du Groupe français pour la leucémie myéloïde chronique.

27. P319: IL7-RECEPTOR EXPRESSION IS FREQUENT IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND PREDICTS SENSITIVITY TO JAK-INHIBITION.

28. S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY.

30. S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL.

31. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.

32. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.

33. Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.

34. Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity.

35. Un cas de syndrome 8p11 associé à une leucémie aiguë érythroblastique et à un lymphome lymphoblastique T traité par l'association ponatinib et chimiothérapie.

38. Cometary Isotopic Measurements.

39. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.

40. A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.

41. Methane Clathrates in the Solar System.

42. Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup.

43. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.

44. Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index.

45. Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.

46. Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.

49. The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases.

Catalog

Books, media, physical & digital resources